US primary research · Flu/COVID-19 COMBO · Adults 50+
A single flu-COVID shot. Will older Americans take it?
What a US survey of 500+ adults aged 50+ reveals about acceptance, the real decision drivers, and the price ceiling for combination vaccines.
VacZine Analytics US consumer survey, May 2024 (754 initiated, 541 completed; ±4% margin of error, adults 50+). Sample from MarketVIEW: Seasonal influenza vaccines (CAT VAMV036).
64%
likely to accept a flu–COVID combo
38%
already had flu + COVID at the same visit
60%
unaware single-shot combos are in development
500+
US adults 50+ surveyed ±4% margin of error
Latest · 2026
Two years on, the survey’s #1 acceptance driver is materialising. Respondents said regulatory approval and a recommendation mattered most — and that pathway is now opening. Moderna’s flu–COVID combination mCOMBRIAX (mRNA-1083) won European Commission marketing authorisation on 22 April 2026 for adults 50+, the first single vaccine approved against both diseases. Separately, its standalone mRNA flu vaccine mRNA-1010 (mFLUSIVA) cleared the US FDA’s VRBPAC 9–0 on 18 June 2026, with a PDUFA decision due 5 August 2026. The combination route is opening first in the EU. Source: CIDRAP →
Finding 01 — Latent demand
A third already double up. Most would accept the single shot.
When asked about a new influenza–COVID-19 combination vaccine, ~64% of respondents said they were ‘likely to accept’ it. And the behaviour is already in place: ~38% received their flu and COVID-19 vaccines on the same day/visit in 2023–24 — closely consistent with real-world co-administration in England (~35%) and US Medicare beneficiaries (36.5% in the later period). A single-shot combination largely formalises what a third of the 50+ population already does.
One reveal~64% were ‘likely to accept’ — yet ~60% had no idea a single-shot flu–COVID combo was even in development. The demand is latent, not informed.
Finding 02 — Decision drivers
Recommendation beats convenience - and platform barely registers.
Asked to rank what would influence their choice (1 = most important, 5 = least), respondents were unambiguous: a regulatory approval plus an HCP recommendation (which we assume follows US ACIP) topped the list. Cutting the number of injections did not move them — the 50+ cohort already receives multiple doses. And despite mass exposure to COVID-19 mRNA vaccines, the mRNA platform itself ranked least important of all.
01
Approval + HCP rec
avg 2.7
—
Fewer injections
not a driver
Last
mRNA platform
avg 4.3
One revealThe mRNA-vs-protein debate matters far less to 50+ consumers than the ACIP / HCP recommendation. Win the recommendation and the platform argument largely takes care of itself.
Finding 03 — The friction points
Acceptance has conditions: price, side-effects, and what's in the mix.
Willingness is real but conditional. Three constraints shape how that demand converts — and the first is commercial, not clinical.
Price premium
Clear resistance
General resistance to a COMBO priced above the sum of its components. Premium pricing is the single biggest commercial constraint on uptake.
Reactogenicity
Trade-off accepted
Mostly ambivalent to potentially higher reactogenicity, with a trend to accepting it as a fair trade-off for fewer injections.
RSV / triple
Neutral to warm
Neutral on adding an RSV antigen, but a trend toward favouring its inclusion in a future flu/COVID/RSV ‘triple’ combination.
One revealRespondents were confident they still understood the need for monovalent COVID-19 doses outside the winter season — a combination shot does not, in their minds, replace off-season boosting.
These findings are a sample. The complete 12-question survey, demographic cuts and the global seasonal influenza value & volume forecast to 2040 — including COMBO and mRNA scenarios — sit inside the live MarketVIEW model. Excel forecast + executive presentation, updated for 2026.
This summary explains what VacZine Analytics Ltd (the data controller) collects when you use this website and the form on this page. The full Privacy Notice is available as a PDF in the footer.
What we collect
If you submit the request form: name, work email, organisation, topic and role indicators, and the IP/User-Agent of your submission. If you accept analytics cookies: aggregate page-visit data via Google Analytics (IP anonymised).
Lawful basis
Consent (UK GDPR Art. 6(1)(a)) for form submissions and any non-essential cookies. Legitimate interest for our own server logs and security monitoring.
Retention
Form submissions are retained for as long as is necessary to fulfil your request and then for up to 24 months for follow-up, unless you ask us to delete sooner.
Your rights
You have rights of access, rectification, erasure, restriction, portability and objection. To exercise any of these, email [email protected]. You may also complain to the UK Information Commissioner's Office (ico.org.uk).
Sharing
We do not sell personal data. Limited processors (email infrastructure, analytics if accepted) handle data on our behalf under written agreements.
Cookie policy
We group cookies and similar technologies into three categories. You control the latter two via the cookie banner (which you can reopen from the footer).
Strictly necessary
Required to run the site. They cannot be disabled. Examples: session integrity, your saved cookie preferences (va.consent.v1 in localStorage).
Analytics (opt-in)
Used only if you accept. Helps us understand which content is read. Example: Google Analytics 4 with IP anonymisation. No personal profiling.
Marketing (opt-in)
Used only if you accept. Measures campaign performance and may enable live-chat widgets. Disabled by default.
Managing your choice
Use the link in the footer at any time. Browser-level controls (e.g. clearing site data) also work.
Terms of use - summary
Use of this website is subject to these terms (in summary) and to our master terms and conditions of business, available as a PDF in the footer for client engagements.
Content on this site is for general information only and does not constitute investment, medical, regulatory, or legal advice. Decisions should be taken with appropriate qualified counsel.
Third-party marks
Product names, trial identifiers, and trademarks shown belong to their respective owners and are used for identification and analytical commentary only.
Governing law
These terms are governed by the laws of England & Wales and subject to the exclusive jurisdiction of the English courts.
Accessibility statement
We're working to make this site usable for the widest possible audience. The current build aims for WCAG 2.1 AA conformance and includes: a skip-to-content link, visible focus styles, semantic landmarks, ARIA labels on interactive controls, sufficient colour contrast against the brand palette, and keyboard operability throughout.
If you encounter a barrier — anything that prevents you from reading or interacting with content — please email [email protected] and we'll address it in our next deploy.
Continuous improvement
We are committed to continuously improving accessibility. If you encounter a barrier — anything that prevents you from reading or interacting with our content — please get in touch and we'll address it in our next deploy. Some decorative SVGs may not yet carry full alt-text equivalents; we treat these as bugs to be fixed as we identify them. Live-chat (if marketing consent is given) is provided by a third party with their own accessibility statement.
Legal Notice & Imprint
Mandatory disclosure of the organisation responsible for this website, in accordance with applicable UK and EU regulations.
Responsible organisation
Legal name: Assay Advantage (VacZine Analytics) Ltd Trading names: Gene Scope Intelligence & VacZine Analytics Registered address: Warren House, Bells Hill, Bishops Stortford, Hertfordshire CM23 2NN, England Companies House registration: 5807728 VAT registration: GB 883 5840 84 Country of incorporation: England & Wales
Data protection framework: UK GDPR & Data Protection Act 2018
Supervisory authority (UK): Information Commissioner's Office (ICO) — ico.org.uk
Privacy policy: View Privacy Policy (PDF)
Cookie policy: View Cookie Policy
Disclaimer
The contents of this website have been prepared with reasonable care. However, Assay Advantage (VacZine Analytics) Ltd accepts no liability for the accuracy, completeness, or timeliness of the information provided on www.genescope-intelligence.com or www.vaczine-analytics.com.
All market intelligence reports and data published on these websites are the intellectual property of Assay Advantage (VacZine Analytics) Ltd and are protected by copyright. Reproduction, distribution, or use of any content without prior written consent is prohibited.
This website may contain links to third-party websites. We have no control over the content or privacy practices of those sites and accept no responsibility for them. External links are provided for informational purposes only.
For questions about this legal notice, please contact us at [email protected] or by post to the registered address above.